BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 28266626)

  • 1. Anordrin Eliminates Tamoxifen Side Effects without Changing Its Antitumor Activity.
    Gu W; Xu W; Sun X; Zeng B; Wang S; Dong N; Zhang X; Chen C; Yang L; Chen G; Xin A; Ni Z; Wang J; Yang J
    Sci Rep; 2017 Mar; 7():43940. PubMed ID: 28266626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The nature of tamoxifen action in the control of female breast cancer.
    Kodama M; Kodama T
    In Vivo; 2001; 15(4):319-25. PubMed ID: 11695224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tamoxifen-induced uterine abnormalities: the role of imaging.
    Ascher SM; Imaoka I; Lage JM
    Radiology; 2000 Jan; 214(1):29-38. PubMed ID: 10644098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tamoxifen and secondary tumours. An update.
    Wilking N; Isaksson E; von Schoultz E
    Drug Saf; 1997 Feb; 16(2):104-17. PubMed ID: 9067122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of Tamoxifen-related Nonalcoholic Fatty Liver Disease in Breast Cancer Patients.
    Chang HT; Pan HJ; Lee CH
    Clin Breast Cancer; 2018 Aug; 18(4):e677-e685. PubMed ID: 29287963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of a new clinically relevant antiestrogen (GW5638) related to tamoxifen on breast and endometrial cancer growth in vivo.
    Dardes RC; O'Regan RM; Gajdos C; Robinson SP; Bentrem D; De Los Reyes A; Jordan VC
    Clin Cancer Res; 2002 Jun; 8(6):1995-2001. PubMed ID: 12060645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tamoxifen mediated human endometrial carcinogenesis may not involve estrogenic pathways: a preliminary note.
    Kuwashima Y; Kurosumi M; Kobayashi Y; Tanuma J; Suemasu K; Higashi Y; Kasamatsu T; Shiromizu K; Matsuzawa M; Kishi K
    Anticancer Res; 1996; 16(5A):2993-6. PubMed ID: 8917418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognosis of tamoxifen-associated endometrial cancer.
    Lasset C; Mignotte H; Bonadona V; Chauvin F
    J Clin Oncol; 1998 Jul; 16(7):2573. PubMed ID: 9667283
    [No Abstract]   [Full Text] [Related]  

  • 9. Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study.
    Swerdlow AJ; Jones ME;
    J Natl Cancer Inst; 2005 Mar; 97(5):375-84. PubMed ID: 15741574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiestrogenic and antifertility actions of Anordrin (2 alpha, 17 alpha-diethynyl-A-nor-5 alpha-androstane-2 beta, 17 beta-diol 2,17-dipropionate).
    Mehta RR; Jenco JM; Chatterton RT
    Steroids; 1981 Dec; 38(6):679-91. PubMed ID: 7336465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tamoxifen and the uterus.
    Vergote I; Neven P; Vanderick G; van Dam P; Van Belle Y; De Sutter Ph; De Prins F; De Muylder X; Claerhout J; Campo R; Albertyn G
    Eur J Cancer; 1998 Aug; 34 Suppl 4():S1-3. PubMed ID: 9917139
    [No Abstract]   [Full Text] [Related]  

  • 12. [Tamoxifen and giant endometrial polyps].
    Caschetto S; Cassaro N; Consalvo P; Caragliano L
    Minerva Ginecol; 2000 Nov; 52(11):459-63. PubMed ID: 11256174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Drug-induced Nonalcoholic Steatohepatitis].
    Miyamura M; Yokota J; Saibara T
    Yakugaku Zasshi; 2016; 136(4):579-82. PubMed ID: 27040342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiestrogen therapy: uncertainties and risk assessment.
    Smith LL; White IN
    Oncology (Williston Park); 1998 Mar; 12(3 Suppl 5):14-22. PubMed ID: 9556786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Risk of endometrial hyperplasia and carcinoma in breast cancer patients receiving adjuvant tamoxifen].
    Semiglazov VF; Maksimov SIa; Bulgatova EA; Meshkova IE; Chepik OF; Berstein LM
    Vopr Onkol; 2003; 49(2):198-204. PubMed ID: 12785205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tamoxifen and the uterus. Proceedings of an international meeting. Brussels, Belgium, 12-13 December 1997.
    Eur J Cancer; 1998 Aug; 34 Suppl 4():S1-67. PubMed ID: 9887891
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of anordrin and its analogue on antifertility.
    Liu CQ; Chen BL; Shen SR; Zhang GZ; Dai MZ
    Contraception; 1985 Sep; 32(3):301-9. PubMed ID: 3841308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Should tamoxifen users be screened for endometrial lesions?
    Neven P; Vergote I
    Lancet; 1998 Jan; 351(9097):155-7. PubMed ID: 9449866
    [No Abstract]   [Full Text] [Related]  

  • 19. Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice.
    Yao K; Lee ES; Bentrem DJ; England G; Schafer JI; O'Regan RM; Jordan VC
    Clin Cancer Res; 2000 May; 6(5):2028-36. PubMed ID: 10815929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tamoxifen-associated malignant endometrial tumors: pathologic features and expression of hormone receptors estrogen-alpha, estrogen-beta and progesterone; a case controlled study.
    Wilder JL; Shajahan S; Khattar NH; Wilder DM; Yin J; Rushing RS; Beaven R; Kaetzel C; Ueland FR; van Nagell JR; Kryscio RJ; Lele SM
    Gynecol Oncol; 2004 Feb; 92(2):553-8. PubMed ID: 14766247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.